Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Daliresp (Roflumilast), Treatment to Reduce COPD

Drug (brand/generic)

Daliresp/Daxas

Company/Licensee

Nycomed

Current Indication

Chronic Obstructive Pulmonary Disease (COPD)

Product Description

Selective phosphodiesterase-4 (PDE4) inhibitor

Therapy Class

Selective phosphodiesterase-4 (PDE4) inhibitor

Market Sector

Respiratory

Development Status

Approved in US and EU
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top